| Metric | Q2 FY27 | Q1 FY27 | Q2 FY26 |
|---|---|---|---|
| Revenue from operations | 1429.7 | 1265.4 | 1220.8 |
| Other income | 4.1 | 4.9 | 27.1 |
| Total income | 1433.8 | 1270.3 | 1248.0 |
| Profit before exceptional items & tax | 151.2 | 137.7 | 162.9 |
| Exceptional items | -1.7 | 63.2 | -8.8 |
| Profit before tax | 150.4 | 199.6 | 153.1 |
| Net profit | 134.1 | 165.5 | 131.5 |
| Operating margin | 10.5% | 15.7% | 12.3% |
A dash means the filing did not report that period; n/m means not meaningful (margin on near-zero revenue). Growth is not shown when either period was a loss. Operating profit excludes other income.
| Net profit, year on year | +2.00% |
|---|---|
| Net profit, quarter on quarter | -19.00% |
| Revenue, year on year | +17.10% |
| Operating profit, year on year | +8.30% |
| Operating profit, quarter on quarter | +10.80% |
NSE results filing, NSE: STAR. Figures extracted from the filing.
Strides Pharma Science Ltd: key numbers
- Share price
- ₹1,100.90
- Market cap
- ₹10,147 Cr
- Revenue (annual)
- ₹4,859 Cr
- Net profit (annual)
- ₹556.2 Cr
- P/E (TTM)
- 16.5×Sector 46.1×
- Promoter holding
- 29.00%+1.09% QoQ
- FII holding
- 27.98%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Strides Pharma Science Ltd
All →Strides Pharma Science Management Change
Strides Pharma's board appointed Biren Gabhawala as Non-Executive Independent Director effective November 1, 2026, for five years. He is a Chartered Accountant with extensive audit and listed-company board experience.
- Execution
- Five-year term effective November 1, 2026
Strides Pharma Science Employee Stock Options
Strides Pharma allotted 7,500 equity shares to an employee exercising options under the Strides ESOP 2016 Plan. Paid-up capital rises to 92,180,214 shares.
Strides Pharma Science Investor Presentation: Key Takeaways
Q2FY27 revenue ₹14,297m (+17.1% YoY), EBITDA ₹2,509m (17.6% margin), reported PAT ₹1,341m (+2.0%). Ex-US revenue surpassed US for the first time; US ~$375m FY28 aspiration pushed beyond FY28.
Strides Pharma Science Results Update
Strides Pharma reported Q2FY27 revenue of ₹14,297m, up 17.1% YoY, and EBITDA of ₹2,509m, up 8.4%, in a press release. Reported PAT rose 2.0% to ₹1,341m.
Strides Pharma Science Board Meeting Date
Strides Pharma will hold a board meeting on 29 October 2026 to consider unaudited quarterly and half-year results. Trading window stays closed from 1 October until 48 hours after results.
Strides Pharma Science Other Announcement
Strides Pharma Science Limited submitted its quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026.